Shanghai, China
Yikon Genomics, founded in 2012, is a dynamic player in the Biotechnology sector, with its headquarters in China. Specializing in reproductive health and personalized cancer genetic services, the company operates a medical laboratory in Suzhou and has a strategic international presence in places like Hong Kong, Spain, and Malaysia.
The company’s innovative spirit is encapsulated in its slogan, "Innovate for The Health of Billions." By harnessing the power of AI and machine learning, Yikon Genomics delivers decentralized, cost-efficient genetic testing solutions aimed at addressing reproductive challenges and genetic risks. Notably, their advancements such as NICS (niPGT-A) and ERT have set benchmarks in genetic science.
Backed by a strong foundation of rigorous clinical validation and a robust network of over 600 medical institutions globally, Yikon Genomics' mission is to aid 100 million families in improving health outcomes. Their latest funding—a CNY250.00M Series D investment in 2021—signals strong investor confidence, with contributions from notable entities like Oriza Holdings and Sinopharm Capital.
Eugene